Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

ISPE Releases ISPE Good Practice Guide: Critical Utilities GMP Compliance


This Guide will be a big benefit to critical utility professionals and smaller manufacturing facilities where they don’t have as much bench depth in their compliance departments.

The International Society for Pharmaceutical Engineering (ISPE) announced the release of its latest guide, ISPE Good Practice Guide: Critical Utilities GMP Compliance – How to Be Compliant and Ready to Prove It. The Guide was cultivated by leading experts to help pharmaceutical organizations achieve and maintain their critical utility systems in a state of control, and then be able to efficiently demonstrate their systems’ Good Manufacturing Practice (GMP) compliance to regulatory inspectors and auditors.

“This Guide will be a big benefit to critical utility professionals and smaller manufacturing facilities where they don’t have as much bench depth in their compliance departments,” said Nik Krpan, President, Cheme Engineering, Guide co-lead. “This resource will help them to identify what are the critical areas they should be focusing on to achieve compliance for their critical utilities and how to host a more efficient audit.”

Key areas addressed in the Guide include:

  • Water systems
  • Pure steam
  • Compressed air
  • Medical gases
  • Processes unique to critical utilities

Purchase the ISPE Good Practice Guide: Critical Utilities GMP Compliance – How to Be Compliant and Ready to Prove It online, available at ISPE.org/Publications/Guidance-Documents, among ISPE’s other detailed education resources on a variety of industry topics.

About ISPE

The International Society for Pharmaceutical Engineering (ISPE) is the world’s largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit ISPE.org for more information.

For more information, contact:

Amy Henry

Marketing Communications Manager

International Society for Pharmaceutical Engineering (ISPE)

Email: ahenry@ispe.org

ISPE.org

Share article on social media or email:

Healthcare’s Shift to Virtual Connection during COVID-19 Crisis Explored by The Beryl Institute


News Image

This paper is grounded in firsthand accounts from organizations and patients and family members who highlight the cause and effect of virtual solutions in medical environments.

Reinforcing its commitment to elevate the human experience in healthcare, The Beryl Institute publishes a new white paper, Maintaining Human Experience in a New Era of Virtual Connection in Healthcare. This paper is grounded in firsthand accounts from organizations and patients and family members who highlight the cause and effect of virtual solutions in medical environments. Participants illustrate the necessity of virtual connection during the COVID-19 crisis in order to maintain the human experience in healthcare.

The virtual connections explored in the paper include the transition to solutions such as telehealth, virtual patient check-in, virtual visits with families, virtual rounding and adaptations to palliative care. Specific examples are provided from individual’s experiences as well as the challenges encountered in making these technology-enabled changes to healthcare practices. Furthermore, the paper depicts how many of these transitions, born from the current healthcare crisis, will be ongoing, changing the nature of human connection in healthcare permanently.

The white paper concludes with the lessons learned and takeaways from this time during the COVID-19 pandemic, such as the importance of technology training, the essential follow-up post virtual visit and the fact that technology and new innovations will bolster human experience, but not replace it.

“This moment and this need for virtual connection in healthcare was seeded before the current crisis ever began, but it has been catalyzed in ways that we could not have imagined,” said Jason Wolf, Ph.D., CPXP, President & CEO of The Beryl Institute. “This needed shift and the future path it paints for healthcare reinforces an essential idea for healthcare; it is in our capacity to care for and connect with one another, regardless of the means we use, that we will succeed.”

We would like to thank contributors from the following healthcare organizations:


  • AdventHealth
  • Barnes-Jewish Hospital
  • Baystate Health
  • Cleveland Clinic
  • InnovaCare Health
  • Mayo Clinic Health System
  • MD Anderson Cancer Center
  • NewYork-Presbyterian
  • Northwell Health
  • Stanford Health Care
  • Sutter Health
  • The University of Chicago Medicine
  • UAB Health System
  • UC Health
  • Vidant Health
  • Zuckerberg San Francisco General Hospital

To download the white paper, please visit: https://www.theberylinstitute.org/store/viewproduct.aspx?id=16686063

###

About The Beryl Institute:

The Beryl Institute is the global community of practice committed to elevating the human experience in healthcare. We believe human experience is grounded in experiences of patients & families, those who work in healthcare and the communities they serve. We define patient experience as the sum of all interactions, shaped by an organization’s culture, that influence patient perceptions across the continuum of care.

Share article on social media or email:

Clean Rooms International Introduces Guardiair to Curb Airborne Contagions


Guardiair Cleans Air with HEPA-Standard Efficiency

Clean Rooms International (CRI) – a leading manufacturer of cleanrooms, workstations and air filtration equipment – has introduced Guardiair, a mobile air filtration system that minimizes airborne contagions and particles with 99.99% efficiency at a 0.3 micron size.

“As businesses across the globe begin to cautiously call employees back to work, it’s essential to reassure staff, customers and other guests that the air they’re breathing is as safe as possible,” said Tim Werkema, President and CEO of CRI. “In this historic moment, we saw an immediate need for effective air filtration systems that decrease the risk of infection and build trust between organizations and the people entering their environments. Guardiair offers the highest quality air filtration and the presence of the mobile unit signifies to people in the vicinity that the air around them is being filtered.”

Drawing on 38 years of cleanroom grade equipment manufacturing and utilizing their standard HEPA filters, CRI’s engineering team developed Guardiair, which collects airborne particles and aerosols. Additional integrations, including a UV-C lamp and ULPA filter, can further increase the level of filtration, making it ideally suited for schools, healthcare settings, corporate environments, restaurants and retail.

Chief Operating Officer, Bret Asper adds: “Our company is dedicated to creating spaces for human innovation, and Guardiair is just one way we are bringing the power of cleanroom technology to new contexts.”

Detailed Product Features:

● HEPA filter: 99.99% efficiency at 0.3 microns

● Merv 8 prefilter

● Indicator light for changing the HEPA filter

● Variable speed control, perforated aluminum face screen and casters with brakes

● Power cord

● Optional integrated UV-C high-output germicidal lamp

● Optional ULPA filter 99.9995% efficiency at minimum particle penetration size (MPPS)

● A variety of powder-coat color options

About Clean Rooms International

Clean Rooms International (CRI) is the partner of choice for cleanroom design, components, hard wall and soft wall cleanrooms, fan filter units and testing and certification services. The company specializes in manufacturing products that allow spaces to maintain extremely low levels of submicron sized particulates, particles not visible to the human eye. Based in Grand Rapids, Michigan, CRI proudly designs and manufactures cleanroom solutions in the USA. For additional information on Guardiair, please visit http://www.guardiair.com or http://www.cleanroomsint.com.

Share article on social media or email:

Peer-Reviewed Study Published on Active Noise Control Device in Simulated NICU


Invictus Medical Improving the lives of newborns

Invictus Medical

We are optimistic that this bench-top study foretells a great means of protecting these vulnerable patients.

A study has been published in the journal PLOS ONE that demonstrates the effectiveness of the Invictus Medical Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal intensive care unit (NICU) environment. The study reported that the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and other bedside devices that would affect the infants cared for in incubators.

“The problems associated with the effect of NICU noise on the incubated preemie patient are documented in the literature in terms of sleep and weight gain, and effective solutions remain elusive.” said George Hutchinson, Invictus Medical’s Chief Executive Officer. “We are optimistic that this bench-top study foretells a great means of protecting these vulnerable patients.”

The greatest attenuation achieved was 14.4 decibels for a typical patient monitor alarm, equating to a 5.5-fold decrease in sound pressure level that the incubator-oriented patient would experience. The study was conducted in the simulation center of the Children’s Hospital of San Antonio, supported by the simulation center’s staff. The results of the study are available at https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235287.

The Neoasis™ is still in development and is not currently being distributed.

About Invictus Medical

Invictus Medical is a San Antonio, Texas-based medical device company that aims to ensure that children are able to attain their developmental milestones. As evidenced by their record of National Science Foundation and National Institutes of Health grants, Invictus Medical has been at the forefront of pediatric care since its founding in 2012. Invictus Medical is a privately held company. For more information about Invictus Medical, please see http://www.invictusmed.com.

Share article on social media or email:

Use of Pembrolizumab Provided Long-Term Benefits in Patients With Metastatic Melanoma, 10-Year Look Shows


Doctor in white coat posing near window

In a study published in JAMA Oncology, Dr. Igor Puzanov took a 10-year look at pembrolizumab use in patients with advanced melanoma

“The study reinforces the fact that immunotherapy can significantly extend the life of patients with melanoma and even lead to cures,” said Dr. Puzanov.

A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published Thursday in the journal JAMA Oncology provides new insights into an important question: whether BRAF V600E/K mutation status or previous BRAF inhibitor (BRAFi) therapy with or without a MEK inhibitor (MEKi) affects response to pembrolizumab (brand name Keytruda) in patients with advanced melanoma.

This retrospective analysis of three randomized clinical trials (KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006) involved 1,558 patients with advanced melanoma and known BRAF tumor status (BRAF wild-type or BRAF V600E/K-mutant melanoma) who had all been treated with pembrolizumab, some of whom had undergone prior treatment with BRAF inhibitors with or without MEK inhibitors.

Patients with BRAF wild-type and BRAF V600E/K-mutant melanoma had objective response rates (ORRs) of 39.8% and 34.3%, respectively, and similar respective rates of both 4-year progression-free survival (PFS; 22.9% and 19.8%) and overall survival (OS; 37.5% and 35.1%).

Patients with BRAF V600E/K-mutant melanoma who received previous BRAFi with or without MEKi had baseline characteristics with worse prognosis — lower ORR (28.4% vs 44.2%), 4-year PFS (15.2% vs 27.8%), and OS (26.9% vs 49.3%) — compared to those who had not received earlier targeted therapy.

The results of this study support the use of pembrolizumab for the treatment of advanced melanoma regardless of BRAF V600E/K mutation status or prior BRAF inhibitor, with or without MEK inhibitor therapy.

“Our findings confirmed the long-term, lasting benefits of pembrolizumab for patients with unresectable advanced melanoma and show that the effect is seen regardless of BRAF mutation status — and regardless of earlier treatment with a BRAF-targeting therapy,” says Dr. Puzanov, who is first author on the new publication. “Coupled with what we know from separate studies about nivolumab, we see a clear picture of the benefits immune checkpoint inhibitors have had for thousands of people with advanced melanoma over the last decade.”

Some 40% of patients with metastatic melanoma have BRAF mutations, meaning a particular gene and protein in their tumor cells is modified. Of that group, 90% have an activating BRAF mutation.

“Our long-term view provides evidence to support giving immunotherapy early in a patient’s treatment, before turning to targeted therapies. This course of treatment is now the standard of care, but this is important affirmation for this approach, which was not standard at the time these patients were treated,” Dr. Puzanov notes.

These study findings may help explain the striking decline in deaths from melanoma reported by the American Cancer Society (ACS) a few months ago. A January 2020 report from the ACS documented a 7%-per-year decline in the overall melanoma death rate between 2013 and 2017 in people ages 20 to 64.

“The study reinforces the fact that immunotherapy can significantly extend the life of patients with melanoma and even lead to cures,” Dr. Puzanov says. “But importantly, we also still see a role for targeted therapies. Having both of these treatment options at our disposal has helped to drive incredible progress against in a cancer type that was almost universally fatal a decade ago.”

The authors note that ongoing randomized controlled trials should support clearer and more specific conclusions about the optimal sequencing of these treatments.

Co-authors on this work include Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Caroline Robert, MD, PhD, of Gustave Roussy, Paris-Sud University, and Omid Hamid, MD, of The Angeles Clinic and Research Institute. A full list of contributors can be found at the study link.

###

For an online version of this release, please visit: https://www.roswellpark.org/newsroom/202007-use-pembrolizumab-provided-long-term-benefits-patients-metastatic-melanoma-10-year

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

Share article on social media or email:

ThePersecuted.org Releases Article on Inequality in South Korea and the Coronavirus Response


News Image

The Republic of South Korea has shined internationally in its response to the coronavirus outbreak. They have received ample praise for their aggressive response to the virus; but there have also been accusations of human rights and religious freedom violations.

The first case of coronavirus in the country was discovered on January 20, 2020. This is the same as for the US.

As of this writing, Korea has had 13,417 cases and 289 deaths. In comparison, the United States has had 3.29 million cases with 137,000 deaths. In other words, the US has 474 times the deaths and 245 times the cases as Korea.

The South Korean leadership learned from the past, adjusting laws after the 2015 MERS outbreak. They took the outbreak seriously, and the message was consistent between scientists and politicians. In other words, people followed instructions to wear masks and isolate. They had widespread contact tracing, and they opened dedicated testing and treatment centers.

For these reasons, Korea has served as a sample for the world. However, their response has been questioned by several analysts. Not in regards to technologies used, but with respect to human rights and religious freedom.

The event that put South Korea on the map was an outbreak in the city of Daegu. Though the first case had appeared on January 20th, the government was reluctant to close its borders to China at the time. Korea did eventually take the outbreak seriously, as mentioned above, but not until several weeks later.

As a result, the virus continued to make its way around, infecting a member of the Shincheonji church, where the virus spread in mid-February to over 4,000 other congregants. Immediately, the government aggressively traced and tested over 200,000 members.

Since that time, the group has stopped all gatherings and offered to contribute financially to the efforts to stop the virus. The 4000+ members who recovered from the virus offered to donate plasma to support vaccine and therapeutics research.

With the spirit of the Korean people to work together as we’ve seen these last few months, there is a promising future of reforming and addressing the inequalities to make a more equitable Korea. But that change will require the voices of the people and the action of their government. Read more about solving South Korea’s systemic inequality issue.

#     #     #

ABOUT THE PERSECUTED:

The Persecuted is a news source dedicated to the factual research and analysis of human rights violations. For more information, visit https://thepersecuted.org/.

Share article on social media or email:

Medial EarlySign and Centric Consulting Join Forces to Increase Hospital Adoption of Clinical AI Solutions


“We see tremendous value in EarlySign’s platform which utilizes machine learning technology to facilitate proactive and strategic interventions for patients at high risk of a range of serious medical conditions,” said Centric’s National Healthcare Practice Lead Marcie Stoshak-Chavez, MD.

Medial EarlySign, a leader in AI-based clinical data solutions to aid in the early detection and prevention of high-burden diseases, and Centric Consulting, a business and technology consulting firm, today announced a partnership to enable US-based hospitals and healthcare organizations to utilize existing data in order to identify and prioritize patients for care.

Combining Centric’s management consulting services with EarlySign’s clinically validated AI-powered solutions, the two companies will work together to help healthcare organizations utilize data-backed insights in order to prioritize patient procedures, deliver focused interventions and re-engage populations.

EarlySign’s Infectious Disease bundle will be a primary focus, given the ongoing COVID-19 pandemic and the imminent arrival of flu season.

“Assisting hospitals in navigating clinical, operational and technology adoption challenges and providing outcome-focused care has always been of utmost importance at Centric. We see tremendous value in EarlySign’s platform which utilizes machine learning technology to help our clients facilitate proactive and strategic interventions for patients at high risk of a range of serious medical conditions,” said Marcie Stoshak-Chavez, MD, National Healthcare Practice Lead at Centric. “EarlySign’s validated framework of clinical solutions is perfectly aligned to address our clients’ immediate and long-term artificial intelligence strategies.”

The partnership follows the recent launch of EarlySign’s Back2Care suite of clinical data solutions and will provide hospitals with the tools to identify and prioritize high-risk patients and implement strategies for re-engagement of services.

The suite offers several solutions aimed at high-burden diseases, including the Infectious Disease bundle, Admissions bundle, Diabetes + Complications bundle, and an Early Detection bundle for diseases such as lung and colorectal cancer.

By using routine medical data collected over the course of care and drawing clinical insights into the best course of action for patients, healthcare organizations can optimize resources to provide more personalized and focused care.

“Working collaboratively with Centric to help drive transformational change will allow us to further our goal of advancing proactive healthcare and keeping populations healthy,” said Jeremy Orr MD, CEO of Medial EarlySign. “We are looking forward to further expanding our reach by engaging with Centric’s broad network to support hospitals in improving patient outcomes and navigating the transition back to necessary screening and care.”

ABOUT CENTRIC CONSULTING

Centric Consulting is a management consulting firm that guides you in the search for answers to complex digital, business and technology problems by asking tough questions, leading crucial conversations and blending our experts with yours. As you navigate what’s next, we can help you conquer change, optimize processes, elevate your technology, and compete in a digital world.

Headquartered in Ohio, with locations across the country and India, Centric has earned annual recognition by Forbes as one of America’s Best Management Consulting Firms since 2016. Visit http://www.centricconsulting.com to learn more.

Connect with Centric Consulting: LinkedIn | Twitter | Facebook | Instagram | YouTube

ABOUT MEDIAL EARLYSIGN

Medial EarlySign helps healthcare systems with early detection and prevention of high-burden diseases. Their suite of outcome-focused software solutions (AlgoMarkers™) find subtle, early signs of high-risk patient trajectories in existing lab results and ordinary EHR data already collected in the course of routine care. EarlySign’s AlgoMarkers and AI-based solutions can help clients identify and prioritize patients at high risk for a broad range of conditions. The algorithmic models developed using the company’s machine learning approach are supported by peer-reviewed research published by internationally recognized health organizations and hospitals. Founded in 2013, Medial EarlySign is headquartered in Tel Aviv, Israel with US headquarters in Colorado. For more information, please visit https://earlysign.com/.

Follow Medial EarlySign on LinkedIn: Medial EarlySign and Twitter: @MedialEarlySign

Share article on social media or email:



NeoTract Designates Dr. Joshua Perkel as UroLift® Center of Excellence


News Image

“We are proud to name Dr. Joshua Perkel as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Joshua Perkel, M.D., Urology Specialists of Georgia in Macon, GA has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Perkel has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. Joshua Perkel as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Surgio Health Featured in an Article Regarding Centura Health Making Innovative Improvements to the SPD Processes


News Image

This era of surgical downtime is the ideal moment for SPDs to refine their processes and prepare for the reopening of elective cases.

Surgio HealthTM, a surgical logistics and instrument tracking management software company, was featured in an article posted by Elizabeth Hofheinz, M.P.H., M.Ed. at OrthoSpineNews related to the proactive steps Centura Health is taking to stay ahead of the bioburden curve in their 17-facility network serving Colorado and western Kansas.

Daniel Whetten, Supply Chain Manager at Centura Health, states, “This era of surgical downtime is the ideal moment for SPDs to refine their processes and prepare for the reopening of elective cases. Instead of furloughing SPD staff, hospitals can have them engage in thoughtful planning so that they can approach cases in a methodical manner instead of always putting out fires.”

This is a critical topic highlighted by an example of a sterilization technician working at Goshen Health in Indiana that skipped one step in a multi-step cleaning process of surgical equipment resulting in more than 1,000 patients potentially being exposed to HIV or hepatitis.

Chris Stewart, CEO of Surgio Health, states, “Like the rest of us, hospital administrations are feeling significant pressure these days. The immediate impact Surgio provides is a sense of control over SPD processes and vendor interaction with your facility…and that extends to a heightened sense of control over patient safety. Since elective surgeries have slowed or have been canceled due to COVID-19, this is the perfect opportunity for SPDs to address ways to improve on departmental processes, workflows and procedures. Vendors dropping off dirty and incomplete instrument sets, SPD staff rushing through the decontamination, cleaning and sterilization process because the OR calls and needs instrument tray’s ASAP…all of that can become a thing of the past with Surgio’s suite of interdepartmental solutions.”

Surgio Health is aware of the complexities and vulnerabilities present in hospital SPDs and the wider surgical supply chain. The Surgio Platform transforms your SPD from a necessary cost center to an OR optimization tool that positively impacts your healthcare value equation.

Chris Allen: “The Surgio platform is nimble and able to respond to what we need. In developing it with Centura, they did not just do an overlay of a computer program on top of what we were already doing. They forced us to take a step back and think, ‘If we can have the moon what would that look like?’”

About Surgio Health

Sterile Processing Departments (SPD) are the lifeblood of the OR’s they support; constantly in motion and under pressure to respond to OR needs at a moment’s notice. One misstep in workflow could lead to a sentinel event that can be detrimental to a hospital, their system, and worst of all: the patient.

Enter Surgio Health — a managed software solution that applies modern technologies to digitally govern process, track instruments, educate and measure Sterile Processing Departments best practice. Surgio is a management hub unique to the healthcare space that brings every influencer, from manufacturer to the operating room, into alignment under one simple, easy-to-use platform. Raise the standards of protection for your hospital and the patients you serve and transform your SPD from a necessary cost center to a department that positively impacts the healthcare value equation.

Share article on social media or email:

Under the Weather® introduces the all-new ShieldPod™ Personal, Portable, Wearable Protective Pod


News Image

With 10-plus years’ experience developing a wide range of portable, pop-up Pods, plus manufacturing capability and in-house product design, UTW is uniquely positioned to develop top-quality products which fit everchanging consumer needs and desires

Under the Weather®(UTW) Chief Executive Officer Rick Pescovitz announced the addition of the all-new ShieldPod™ to the company’s lineup of Pods.

“Our newest COVID-19 product, the ShieldPod™, was designed originally to help protect healthcare workers (MediPod™) from possible COVID-19 exposure but it generated so much buzz and customer requests outside the healthcare industry that we modified the style to accommodate anyone looking for added peace of mind or practicing safe social distancing” adds Pescovitz.

The patent-pending design is a lightweight, protective barrier with a slim profile that pops open and folds flat in seconds. It’s easy to wear, use and store, slips easily over the head with clear panels on three sides for 270° viewing. Padded, adjustable shoulder straps, a waist belt, raised front panel, large armholes on two sides and open bottom offer full range of movement and more options for hand placement whether you’re sitting or walking around. The trim is a neutral dark gray.

“With 10-plus years’ experience developing a wide range of portable, pop-up Pods, plus manufacturing capability and in-house product design, UTW is uniquely positioned to develop top-quality products which fit everchanging consumer needs and desires,” said Kelly Mahan, UTW president. “We also have a legion of loyal brand advocates that helps us by testing our products and providing feedback which ensures the design and quality of our pods is top notch.”

The potential use cases for the ShieldPod are endless, such as: Customer-facing retail employees; teachers; call center employees; taxi and ride-share drivers; church groups; public transportation employees; subway and train commuters; air travelers; workplace huddles; public servants; caregivers; nursing and retirement homes; urban dwellers; and more.

Like all UTW Pods, the ShieldPod uses one-piece wire frame construction, so it’s flexible, pops open and folds down in seconds, with zero assembly required. ShieldPod wearers, and others around them, are protected in an instant.

Thanks to early rave reviews from product testers, including educators, checkout staff and transportation workers, the ShieldPod is in high demand. Affordably priced at $79.99 USD. It is currently being sold as a pre-order exclusively at UTWPods.com. Fulfillment for pre-orders is expected to begin mid-to-late July 2020.

About Under the Weather

The brand of choice for outdoor enthusiasts the world over, Under the Weather has been home to the original pop-up WeatherPod™ since it was established in 2010 in Cincinnati, Ohio. First to market, Under the Weather’s mission is to provide innovative weather-protection solutions for backpackers, campers, sports parents, tailgating fans, music festival buffs and anyone determined to “Be There. Weather, or Not.™”

Under the Weather has been featured on ABC’s “Shark Tank”; NBC’s “Today” show; “The Ellen DeGeneres Show”; the “Rachael Ray Show”; Hallmark Channel’s “Home & Family” and Weather Channel’s “AMHQ: America’s Morning Headquarters.”

Visit UTWPods.com for more information. Stay connected with Under the Weather on Facebook (fb.me/UTWPods), Instagram (@UTWPods) and Twitter (@UTWPods).

Share article on social media or email: